Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: John S. Baker who wrote (370)	8/15/1998 10:03:00 AM
From: muddphudd	Read Replies (2) \| Respond to of 586

Wow! Its been dead here for a while. Copied this from the Yahoo thread: "How are our prospects affected by the news this week that an FDA advisory panel had recommended approval of Hoechst's Arava drug, a new therapy for the treatment of rheumatoid arthritis. It provides relief from the disease's symptoms and retards the structural damage that the disease causes. The panel also recommended to the FDA that the drug's label be expanded to include improve to the sufferer's physical functioning.The NDA was filed on March 10 and the FDA designated the drug for priority review." Thoughts??

To: John S. Baker who wrote (370)	8/15/1998 10:05:00 AM
From: muddphudd	Read Replies (1) \| Respond to of 586

Follow up: "This is a good link talking about Arava. abcnews.com It looks like it has problems. 70% of the people who have RA are women and this drug causes birth defects. Granted most of the women who get RA are probably past the child bearing years but it still makes you wonder. It also causes liver damage like most of the other so called RA cures. It doesn't cure crippling RA, which is the target market for the Prosorba column. I don't see it as a big threat to CYPB. Just another drug that helps some people some of the time but causes more problems latter. "